X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/29/2871603/0/en/Pediatric-Brain-Tumor-Foundation-celebrates-FDA-approval-of-Day-One-Biopharmaceuticals-OJEMDA-new-treatment-for-common-pediatric-brain-tumor-type.html
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric#:~:text=On%20April%2023%2C%202024%2C%20the,rearrangement%2C%20or%20BRAF%20V600%20mutation.
https://www.globenewswire.com/news-release/2024/04/23/2868089/0/en/Day-One-s-OJEMDA-tovorafenib-Receives-US-FDA-Accelerated-Approval-for-Relapsed-or-Refractory-BRAF-altered-Pediatric-Low-Grade-Glioma-pLGG-the-Most-Common-Form-of-Childhood-Brain-Tu.html
https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated
https://www.globenewswire.com//news-release/2024/02/26/2835523/0/en/Day-One-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Progress.html
https://www.globenewswire.com//news-release/2024/01/17/2810655/0/en/Day-One-Announces-Two-New-Appointments-to-Board-of-Directors.html
https://www.globenewswire.com//news-release/2023/12/19/2798477/0/en/Day-One-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/11/17/2782501/0/en/Day-One-Announces-Tovorafenib-FIREFLY-1-Data-Published-in-Nature-Medicine.html
https://www.globenewswire.com//news-release/2023/11/14/2780040/0/en/Day-One-to-Participate-in-the-Piper-Sandler-35th-Annual-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/11/06/2774566/0/en/Day-One-Reports-Third-Quarter-2023-Financial-Results-and-Corporate-Progress.html
Market Place
Share 
